Richard C. Mohs, PhD, is Vice President of Clinical Development at Agenebio. He also serves as Chief Scientific Officer for the Global Alzheimer’s Platform (GAP) Foundation, which works to improve the speed and quality of drug development for Alzheimer’s disease. Dr. Mohs retired in 2015 from Eli Lilly and Company, where he was Vice President for Neuroscience Early Clinical Development and Distinguished Research Fellow within Lilly Research Laboratories. From 2011 through 2015, he led a team of clinical scientists conducting first in humans through proof-of-concept studies of molecules being developed for the treatment of brain diseases, including Alzheimer's. Dr. Mohs joined Lilly in 2002, working initially in the early phase development group.
Dr. Mohs received his doctorate is psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford University Medical School. Before joining Eli Lilly in 2002, he spent 23 years with the Mount Sinai School of Medicine where he was professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center.
Current role